{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"160","value":"341"},{"groupId":"OG001","spread":"1270","value":"1020"},{"groupId":"OG003","value":"673"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Results for this outcome measure was reported for Part 2 and Part 3 combined.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 2 and 3 Combined: 0.1 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 2 and 3 Combined: 0.2 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 2 and 3 Combined: 0.3 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 2 and 3 Combined: 0.4 mg/kg"},{"description":"Participants with advanced relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG004","title":"Part 2 and 3 Combined: 0.5 mg/kg"}],"paramType":"MEAN","populationDescription":"PK evaluable set included treated participants with adequate blood sampling to estimate at least one PK parameter. Here, \"Number of participants analyzed\" signifies number of evaluable participants for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Part 2 and 3: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1","title":"Part 2 and 3 Combined: Maximum Plasma Concentration (Cmax) of TTI-621","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}